Makoto Kitade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Makoto Kitade has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Akihiko Matsumine
Department of Orthopaedics and Rehabilitation Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
3 shared publications - Tetsuro Tani
Osaka University Graduate School of Medicine, Suita, Japan
2 shared publications - Ai Takahashi
University of Fukui, Fukui-shi, Japan
1 shared publication Akihiko Matsumine
Department of Orthopaedics and Rehabilitation Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
1 shared publication- Hideaki Nakajima
Department of Orthopaedics and Rehabilitation Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
1 shared publication - Hidehiko Okazawa
Life Science Innovation Center, School of Medical Sciences, University of Fukui, Fukui, Japan
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Springer Nature in Journal of Medical Case Reports
Periprosthetic joint infection during biologic therapy in rheumatoid arthritis: two cases successfully managed without implant removal—a case report
Background: Periprosthetic joint infection (PJI) is a devastating complication of arthroplasty, and in patients with rheumatoid arthritis (RA) receiving biological disease-modifying antirheumatic drugs (b-DMARDs), its diagnosis and management are particularly challenging. Because b-DMARDs blunt the acute-phase response, PJI in these patients may present with attenuated fever and C-reactive protein (CRP), delaying diagnosis. Whether late acute hematogenous PJI arising during biologic therapy can be managed with retention of the prosthesis remains uncertain. Case presentation: We report two Japanese women with long-standing RA who developed late acute hematogenous PJI during b-DMARD therapy. Case 1, a 77-year-old Japanese woman on etanercept plus methotrexate (MTX) 9 years after left bipolar hemiarthroplasty, presented in septic shock with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia and multifocal abscesses (left hip, right acromioclavicular joint, bilateral iliopsoas). Case 2, a 63-year-old Japanese woman on tocilizumab plus MTX 2 years after total elbow arthroplasty, had progressive elbow pain and a draining sinus despite a CRP of 0.01 mg/dL; cultures yielded Listeria monocytogenes . In both cases, b-DMARDs were discontinued and pathogen-directed antibiotics were administered. The prostheses were retained: in Case 1 after bedside incision and drainage of the affected joints without formal debridement (because of hemodynamic instability), and in Case 2 after open debridement with polyethylene liner exchange. Neither prosthesis has shown recurrence at 5-year follow-up, and RA has subsequently been controlled with conventional synthetic DMARDs (cs-DMARDs) alone. Conclusions: Two learning points emerge. First, b-DMARDs—particularly interleukin-6-receptor blockade—can markedly attenuate the clinical and laboratory signature of PJI, so a high index of suspicion is essential even when fever and CRP are absent. Second, these two cases illustrate that, in carefully selected patients, late acute hematogenous PJI arising during biologic therapy can be managed with retention of the prosthesis when b-DMARDs are promptly discontinued, the causative pathogen is identified, and adequate source control is achieved. These observations are hypothesis-generating and do not establish the general effectiveness of debridement, antibiotics, and implant retention (DAIR) in this population. Both patients were maintained on cs-DMARDs without biologic reintroduction; whether biologics should be permanently discontinued after PJI should be decided individually.
- 13 November 2026
- Published by Springer Nature in Journal of Medical Case Reports
Open AccessPeriprosthetic joint infection during biologic therapy in rheumatoid arthritis: two cases successfully managed without implant removal—a case report
Background: Periprosthetic joint infection (PJI) is a devastating complication of arthroplasty, and in patients with rheumatoid arthritis (RA) receiving biological disease-modifying antirheumatic drugs (b-DMARDs), its diagnosis and management are particularly challenging. Because b-DMARDs blunt the acute-phase response, PJI in these patients may present with attenuated fever and C-reactive protein (CRP), delaying diagnosis. Whether late acute hematogenous PJI arising during biologic therapy can be managed with retention of the prosthesis remains uncertain. Case presentation: We report two Japanese women with long-standing RA who developed late acute hematogenous PJI during b-DMARD therapy. Case 1, a 77-year-old Japanese woman on etanercept plus methotrexate (MTX) 9 years after left bipolar hemiarthroplasty, presented in septic shock with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia and multifocal abscesses (left hip, right acromioclavicular joint, bilateral iliopsoas). Case 2, a 63-year-old Japanese woman on tocilizumab plus MTX 2 years after total elbow arthroplasty, had progressive elbow pain and a draining sinus despite a CRP of 0.01 mg/dL; cultures yielded Listeria monocytogenes . In both cases, b-DMARDs were discontinued and pathogen-directed antibiotics were administered. The prostheses were retained: in Case 1 after bedside incision and drainage of the affected joints without formal debridement (because of hemodynamic instability), and in Case 2 after open debridement with polyethylene liner exchange. Neither prosthesis has shown recurrence at 5-year follow-up, and RA has subsequently been controlled with conventional synthetic DMARDs (cs-DMARDs) alone. Conclusions: Two learning points emerge. First, b-DMARDs—particularly interleukin-6-receptor blockade—can markedly attenuate the clinical and laboratory signature of PJI, so a high index of suspicion is essential even when fever and CRP are absent. Second, these two cases illustrate that, in carefully selected patients, late acute hematogenous PJI arising during biologic therapy can be managed with retention of the prosthesis when b-DMARDs are promptly discontinued, the causative pathogen is identified, and adequate source control is achieved. These observations are hypothesis-generating and do not establish the general effectiveness of debridement, antibiotics, and implant retention (DAIR) in this population. Both patients were maintained on cs-DMARDs without biologic reintroduction; whether biologics should be permanently discontinued after PJI should be decided individually.
- 24 October 2025
- Published by Springer Nature in Archives of orthopaedic and trauma surgery
- Vol. 145 (1) , 1-7
Determinants of 6-month mortality in super-old patients with femoral neck fractures: the role of surgery and preoperative status in Japan
- 24 October 2025
- Published by Springer Nature in Archives of orthopaedic and trauma surgery
- Vol. 145 (1) , 1-7
Determinants of 6-month mortality in super-old patients with femoral neck fractures: the role of surgery and preoperative status in Japan
- Open Access
- 6 September 2025
- Published by Springer Nature in International Orthopaedics
- Vol. 49 (10) , 2509-2517
Long-term results of the metaphyseal-loading anterolaterally flared anatomic femoral stem for total hip arthroplasty
Background: Patients with secondary hip osteoarthritis due to developmental dysplasia of the hip (DDH) often have abnormal femoral morphology, making stem design critical for long-term outcomes. The FMS-anatomic stem previously demonstrated favourable mid-term results. Its successor, the Anatomic Fit stem, was developed with a reduced hydroxyapatite-coated area to enhance proximal load transfer and a narrower lateral flare to facilitate insertion. This study aimed to analyze the long-term clinical and radiographic outcomes of these stems. Methods: The one-hundred seventy-eight hips underwent total hip arthroplasty using either the FMS-anatomic or Anatomic Fit stem. After applying exclusion criteria, 119 hips (36 FMS-anatomic and 83 Anatomic Fit) were analyzed. Clinical and radiographic outcomes were assessed, and stem survival was evaluated using Kaplan–Meier analysis with stem revision as the endpoint. Results: The 15- and 20-year survival rates were 97.2% and 94.4% for the FMS-anatomic stem, and 98.8% for the Anatomic Fit stem at both time points, with no significant difference. Spot welds were observed in nearly all cases, but their distribution differed significantly: zones 2 and 6 in the FMS-anatomic group and zones 1 and 7 in the Anatomic Fit group (P < 0.05). Stress shielding of Grade 3 or higher occurred in 16.5% of FMS-anatomic stems and 33.7% of Anatomic Fit stems (P < 0.05). Conclusions: Both stems showed excellent long-term survival and proximal fixation. However, the Anatomic Fit stem did not reduce stress shielding, despite its modified design intended to improve load transfer.
- 6 September 2025
- Published by Springer Nature in International Orthopaedics
- Vol. 49 (10) , 2509-2517
Open AccessLong-term results of the metaphyseal-loading anterolaterally flared anatomic femoral stem for total hip arthroplasty
Background: Patients with secondary hip osteoarthritis due to developmental dysplasia of the hip (DDH) often have abnormal femoral morphology, making stem design critical for long-term outcomes. The FMS-anatomic stem previously demonstrated favourable mid-term results. Its successor, the Anatomic Fit stem, was developed with a reduced hydroxyapatite-coated area to enhance proximal load transfer and a narrower lateral flare to facilitate insertion. This study aimed to analyze the long-term clinical and radiographic outcomes of these stems. Methods: The one-hundred seventy-eight hips underwent total hip arthroplasty using either the FMS-anatomic or Anatomic Fit stem. After applying exclusion criteria, 119 hips (36 FMS-anatomic and 83 Anatomic Fit) were analyzed. Clinical and radiographic outcomes were assessed, and stem survival was evaluated using Kaplan–Meier analysis with stem revision as the endpoint. Results: The 15- and 20-year survival rates were 97.2% and 94.4% for the FMS-anatomic stem, and 98.8% for the Anatomic Fit stem at both time points, with no significant difference. Spot welds were observed in nearly all cases, but their distribution differed significantly: zones 2 and 6 in the FMS-anatomic group and zones 1 and 7 in the Anatomic Fit group (P < 0.05). Stress shielding of Grade 3 or higher occurred in 16.5% of FMS-anatomic stems and 33.7% of Anatomic Fit stems (P < 0.05). Conclusions: Both stems showed excellent long-term survival and proximal fixation. However, the Anatomic Fit stem did not reduce stress shielding, despite its modified design intended to improve load transfer.
- Open Access
- 23 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (1) , 116
Evaluation of (R)-[11C]PK11195 PET/MRI for Spinal Cord-Related Neuropathic Pain in Patients with Cervical Spinal Disorders
Activated microglia are involved in secondary injury after acute spinal cord injury (SCI) and in development of spinal cord-related neuropathic pain (NeP). The aim of the study was to assess expression of translocator protein 18 kDa (TSPO) as an indicator of microglial activation and to investigate visualization of the dynamics of activated microglia in the injured spinal cord using PET imaging with (R)-[11C]PK11195, a specific ligand for TSPO. In SCI chimeric animal models, TSPO was expressed mainly in activated microglia. Accumulation of (R)-[3H]PK11195 was confirmed in autoradiography and its dynamics in the injured spinal cord were visualized by (R)-[11C]PK11195 PET imaging in the acute phase after SCI. In clinical application of (R)-[11C]PK11195 PET/MRI of the cervical spinal cord in patients with NeP related to cervical disorders, uptake was found in cases up to 10 months after injury or surgery. No uptake could be visualized in the injured spinal cord in patients with chronic NeP at more than 1 year after injury or surgery, regardless of the degree of NeP. However, a positive correlation was found between standardized uptake value ratio and the severity of NeP, suggesting the potential of clinical application for objective evaluation of chronic NeP.
- 23 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (1) , 116
Open AccessEvaluation of (R)-[11C]PK11195 PET/MRI for Spinal Cord-Related Neuropathic Pain in Patients with Cervical Spinal Disorders
Activated microglia are involved in secondary injury after acute spinal cord injury (SCI) and in development of spinal cord-related neuropathic pain (NeP). The aim of the study was to assess expression of translocator protein 18 kDa (TSPO) as an indicator of microglial activation and to investigate visualization of the dynamics of activated microglia in the injured spinal cord using PET imaging with (R)-[11C]PK11195, a specific ligand for TSPO. In SCI chimeric animal models, TSPO was expressed mainly in activated microglia. Accumulation of (R)-[3H]PK11195 was confirmed in autoradiography and its dynamics in the injured spinal cord were visualized by (R)-[11C]PK11195 PET imaging in the acute phase after SCI. In clinical application of (R)-[11C]PK11195 PET/MRI of the cervical spinal cord in patients with NeP related to cervical disorders, uptake was found in cases up to 10 months after injury or surgery. No uptake could be visualized in the injured spinal cord in patients with chronic NeP at more than 1 year after injury or surgery, regardless of the degree of NeP. However, a positive correlation was found between standardized uptake value ratio and the severity of NeP, suggesting the potential of clinical application for objective evaluation of chronic NeP.